SBIR/STTR Research Award

Neurogastric electrical stimulation for treating chemotherapy-induced emesis

Award identifier 9c3fda2ce5aafa9a277d9a354f39ac855810a75440f71e05bdc5120950b0e08fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TRANSTIMULATION RESEARCH INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
DLBFL8DKL6Z3
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. Over one million people get cancer each year. Approximately one out of every two American men and one out of every three A merican women will have some type of cancer at some point during their lifetime. Cisplatin is one of the most commonly used drugs in chemotherapy for cancers. However, severe adverse events resulting from chemotherapies, mainly nausea and vomiting may be m uch more distressing to a patient than future concerns of life expectancy. In fact, some patients choose to discontinue potentially curative therapy because of severe Cisplatin-induced nausea and vomiting. Antiemetic agents are the most common inte rvention in the management of chemotherapy-induced nausea and vomiting in cancer patients. The basis for antiemetic therapy is the neurochemical control of vomiting. However, currently, there are no satisfactory therapies for treating chemotherapy-induced emesis, especially delayed emesis. Neurogastric electrical stimulation (nGES) has recently been proposed and found effective in treating nausea and vomiting in patients with gastroparesis. Its central and neuronal mechanisms have recently been elucidated. It is hypothesized that nGES is effective in treating chemotherapy-induced emesis. The long-term aim of this project is to develop an endoscopically implantable microstimulator for the treatment of chemotherapy-induced emesis. The aim of this Phase I project is to study the feasibility of this novel method for treating chemotherapy- induced emesis. Specific objectives include a feasibility study in an animal model of Cisplatin-induced emesis, central and neuronal mechanistic studies involving nGES a nd optimization of the nGES therapy based on the mechanisms of action. A competitive team has been established, including experts in gastrointestinal electrical stimulation, physiology of the central nervous system and micro-stimulators. PUBLIC HEA LTH RELEVANCE: Chemotherapy-induced emesis is one of major problems in the treatment of patients with cancer and occurs in more than 90% of cases with certain medications, such as Cisplatin. With the recent advancement of anti-emetic medications, acute eme sis is better controlled; however, delayed emesis remains a big challenge. A novel method of neurogastric electrical stimulation (nGES) is proposed in this project for the treatment of chemotherapy-induced emesis. Preliminary data supports this novel conce pt and experiments are designed to test the feasibility of the proposed method.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

12 SBIR/STTR records share this UEI (2003–2020). Reported award amounts total $6,124,060. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.